Treatment

Join us for a series of educational sessions where team members across multiple disciplines can receive case-specific guidance from expert faculty on how to recognize and manage immune-related adverse events.

A biosimilar is a biological medical product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved biological product.

Bispecific antibodies are an emerging class of novel immunotherapy agents that have led to major breakthroughs in treating hematologic malignancies—and have promising applications for solid tumors.

As immunotherapy for cancer continues to evolve, the ACCC Immuno-Oncology (IO) Institute is at the forefront of developing critical educational materials to empower healthcare professionals across care delivery settings.